Two NIH Labs Cease Reagent Production

Contamination concerns at cell therapy and radioactive tracer facilities spur production shutdowns.

By | April 20, 2016

Clinical Research Center at the NIHWIKIMEDIA, NIHThe production of reagents at a cell therapy lab and a positron emission tomography (PET) facility, both part of the National Institutes of Health (NIH), is on hold because of concerns about safety and contamination, NPR’s Shots reported Tuesday (April 19).

“There is no evidence that any patients have been harmed, but a rigorous clinical review will be undertaken,” the NIH told NPR in a statement. “NIH will not enroll new patients in affected trials until the issues are resolved.”

The National Cancer Institute (NCI)-based cell therapy lab makes treatments for cancer immunotherapy clinical trials. Kite Pharma, which is conducting trials in partnership with the NCI, said in a statement that ongoing studies will continue, but “no new patients will be enrolled until the review is complete.” 

Nature News reported that problems at the NCI lab, run by Steven Rosenberg, involve air flow and staff clothing. “We are working very hard and very collaboratively with [Rosenberg] and NCI and others across NIH to identify a path forward so that we can have him continue his research,” NIH Deputy Director Kathy Hudson told Nature News.

The PET facility is part of the National Institute of Mental Health.

The lab suspensions follow on the heels of other recent safety issues at the agency. Last June, NIH’s production of drugs for 46 clinical trials stopped after fungal contamination was detected in batches of a medicine that had been given to patients.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. How Gaining and Losing Weight Affects the Body
    Daily News How Gaining and Losing Weight Affects the Body

    Millions of measurements from 23 people who consumed extra calories every day for a month reveal changes in proteins, metabolites, and gut microbiota that accompany shifts in body mass.

  2. That Other CRISPR Patent Dispute
    Daily News That Other CRISPR Patent Dispute

    The Broad Institute and Rockefeller University disagree over which scientists should be named as inventors on certain patents involving the gene-editing technology.

  3. Neurons Use Virus-Like Proteins to Transmit Information
  4. EPO Revokes Broad’s CRISPR Patent
    The Nutshell EPO Revokes Broad’s CRISPR Patent

    Shortly after ruling out the earliest priority dates on a foundational patent for CRISPR gene-editing technology, the European Patent Office rescinded the patent entirely—and more are likely to follow.

AAAS